Reduced Thrombospondin-1 at Presentation Predicts Disease Progression in Superficial Bladder Cancer

Goddard, Jonathan Charles; Sutton, Christopher; Jones, J. Louise; O’Byrne, Kenneth J.; Kockelbergh, Roger

doi:10.1016/s0302-2838(02)00372-x

Cited by 49 publications

(45 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the treatment of invasive bladder cancer with radical cystectomy (5), up to 50% of patients develop metastases and 5-year survival is low (6). Increased microvessel density (7) and high expression of VEGF-A correlate with poor prognosis (8), progression (9,10), and shorter survival of patients with bladder cancer (11). We aimed at elucidating differences at the molecular level between tumor-associated blood vasculature and normal vasculature, which might serve as therapeutic targets or as prognostic biomarkers.…”

Section: Introductionmentioning

confidence: 99%

Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-A–Induced Angiogenesis

et al. 2013

View full text Add to dashboard Cite

Tumor-associated blood vessels differ from normal vessels and proteins present only on tumor vessels may serve as biomarkers or targets for antiangiogenic therapy in cancer. Comparing the transcriptional profiles of blood vascular endothelium from human invasive bladder cancer with normal bladder tissue, we found that the endothelial cell-specific molecule endocan (ESM1) was highly elevated on tumor vessels. Endocan was associated with filopodia of angiogenic endothelial tip cells in invasive bladder cancer. Notably, endocan expression on tumor vessels correlated strongly with staging and invasiveness, predicting a shorter recurrence-free survival time in noninvasive bladder cancers. Both endocan and VEGF-A levels were higher in plasma of patients with invasive bladder cancer than healthy individuals. Mechanistic investigations in cultured blood vascular endothelial cells or transgenic mice revealed that endocan expression was stimulated by VEGF-A through the phosphorylation and activation of VEGFR-2, which was required to promote cell migration and tube formation by VEGF-A. Taken together, our findings suggest that disrupting endocan interaction with VEGFR-2 or VEGF-A could offer a novel rational strategy to inhibit tumor angiogenesis. Furthermore, they suggest that endocan might serve as a useful biomarker to monitor disease progression and the efficacy of VEGF-A–targeting therapies in patients with bladder cancer. Cancer Res; 73(3); 1097–106. ©2012 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-A–Induced Angiogenesis

et al. 2013

View full text Add to dashboard Cite

show abstract

“…40 -42 The clinical significance of angiogenesis, measured as MVD, has been demonstrated for several tumor types, including gastrointestinal, breast, bladder and renal cell carcinomas. [43][44][45][46] Studies that compared various endothelial cell markers (i.e., CD31, CD34 and factor VIII) have shown that CD34 is a sensitive endothelial cell marker for measuring MVD. 47,48 At the present time, the clinical significance of MVD as an independent predictor of pathologic stage and recurrence in PCa remains unclear.…”

mentioning

confidence: 99%

Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL‐1), CD44v6 and microvessel density for prostate cancer

Ekici

Cerwinka

Duncan

et al. 2004

Intl Journal of Cancer

View full text Add to dashboard Cite

Despite the development of nomograms designed to evaluate a prostate cancer (PCa) patient's prognosis, the information has been limited to PSA, clinical stage, Gleason score and tumor volume estimates. We compared the prognostic potential of 4 histologic markers, hyaluronic acid (HA), HYAL-1-type hyaluronidase (HAase), CD44v6 and microvessel density (MVD) using immunohistochemistry. HA is a glycosaminoglycan that promotes tumor metastasis.

show abstract

“…Previous studies suggested that BVD provides significant information on prognosis and survival in patients with bladder cancer (Streeter & Harris, 2002;Goddard, 2003). However, other investigators were less supportive for the prognostic value of BVD, especially in patients with non-muscle-invasive bladder cancer (NMIBC) (Korkolopoulou, et al, 2001;Ioachim, et al, 2006;Miyata, et al, 2006).…”

Section: Angiogenesis and Lymphangiogenesis In Bladder Cancermentioning

confidence: 99%

Angiogenesis and Lymphangiogenesis in Bladder Cancer

Miyata¹,

Sakai²,

Kanda³

2012

Bladder Cancer - From Basic Science to Robotic Surgery

View full text Add to dashboard Cite

Reduced Thrombospondin-1 at Presentation Predicts Disease Progression in Superficial Bladder Cancer

Cited by 49 publications

References 10 publications

Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-A–Induced Angiogenesis

Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-A–Induced Angiogenesis

Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL‐1), CD44v6 and microvessel density for prostate cancer

Angiogenesis and Lymphangiogenesis in Bladder Cancer

Contact Info

Product

Resources

About